Urine samples from school-aged children from Nérékoro in Ségou region of Mali. Three samples on right show visible haematuria, which indicates infection with S haematobium. Three samples on left are not haematuric at visual inspection but could still contain abnormal number of red blood cells. Urine cloudiness (third sample from left) is early sign of abnormality. Photo Credit: The Lancet
In an editorial in the August 13 edition of The Lancet, authors representing the Sabin Vaccine Institute, the World Health Organization (WHO) and the Imperial College of London call for increased supplies of praziquantel for the African continent. Praziquantel is the only commercially available treatment for human schistosomiasis, a devastating neglected tropical disease (NTD) affects an estimated 200-600 million people worldwide, with the vast majority of cases occurring in Africa, and causes chronic anemia and inflammation associated with severe disability among children, adolescents and young adults. Schistosomiasis produces a disease burden that could exceed that of malaria.
NTDs are devastating, disabling and debilitating parasitic and bacterial infections that adversely affect the poorest 1.4 billion people worldwide living on $1.25 a day. Such conditions promote poverty because of their impact on child growth and development, pregnancy outcome, and worker productivity, all of which adversely impact the earning capacity of already impoverished individuals and communities.
Authors Dr. Peter Hotez (Sabin Vaccine Institute), Dr. Lorenzo Savioli (WHO), Dr. Dirk Engels (WHO) and Dr. Alan Fenwick (Imperial), emphasize that because an estimated one billion tablets are needed to treat 400 million people annually or every other year, at least 10-20 times the currently donated praziquantel is necessary to increase treatment for schistosomiasis in Africa.
The authors conclude by stating that, “… praziquantel is urgently needed for sub-Saharan Africa now, and the current failure of the global community to provide access to this essential medicine is impeding sustainable development in Africa. The shortages of praziquantel should be treated as an African humanitarian crisis.”
Read the full article here
